Charde Shrikant, Mudgal Madri, Kumar Lajwinder, Saha Ranendra
Formulation Development and Pharmacokinetics Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani- 333031, Rajasthan, India.
AAPS PharmSciTech. 2008;9(1):182-90. doi: 10.1208/s12249-007-9031-7. Epub 2008 Jan 30.
The purpose of this research was to develop and evaluate buccal mucoadhesive controlled release tablets of lercanidipine hydrochloride using polyethylene oxide and different viscosity grades of hydroxypropyl methylcellulose individually and in combination. Effect of polymer type, proportion and combination was studied on the drug release rate, release mechanism and mucoadhesive strength of the prepared formulations. Buccal mucoadhesive tablets were made by direct compression and were characterized for content uniformity, weight variation, friability, surface pH, thickness and mechanism of release. In order to estimate the relative enhancement in bioavailability one optimized formulation was evaluated in rabbits. Further, placebo tablets were also evaluated for acceptability in human subjects. Results indicated acceptable physical characteristics of designed tablets with good content uniformity and minimum weight variation. Drug release and mucoadhesive strength were found to depend upon polymer type, proportion and viscosity. The formulations prepared using poly ethylene oxide gave maximum mucoadhesion. The release mechanism of most formulations was found to be of anomalous non-Fickian type. In vivo studies of selected formulation in rabbits demonstrated significant enhancement in bioavailability of lercanidipine hydrochloride relative to orally administered drug. Moreover, in human acceptability studies of placebo formulations, the designed tablets adhered well to the buccal mucosa for more than 4 h without causing any discomfort. It may be concluded that the designed buccoadhesive controlled release tablets have the potential to overcome the disadvantage of poor and erratic oral bioavailability associated with the presently marketed formulations of lercanidipine hydrochloride.
本研究的目的是单独或联合使用聚环氧乙烷和不同粘度等级的羟丙基甲基纤维素,开发并评估盐酸乐卡地平的口腔粘膜粘附控释片。研究了聚合物类型、比例和组合对所制备制剂的药物释放速率、释放机制和粘膜粘附强度的影响。通过直接压片法制备口腔粘膜粘附片,并对其含量均匀度、重量差异、脆碎度、表面pH值、厚度和释放机制进行表征。为了评估生物利用度的相对提高,在兔体内对一种优化制剂进行了评价。此外,还对安慰剂片在人体受试者中的可接受性进行了评估。结果表明,所设计片剂的物理特性可接受,含量均匀度良好,重量差异最小。发现药物释放和粘膜粘附强度取决于聚合物类型、比例和粘度。使用聚环氧乙烷制备的制剂具有最大的粘膜粘附性。发现大多数制剂的释放机制为非菲克型异常释放。所选制剂在兔体内的研究表明,相对于口服给药,盐酸乐卡地平的生物利用度显著提高。此外,在安慰剂制剂的人体可接受性研究中,所设计的片剂在口腔粘膜上良好粘附超过4小时,且未引起任何不适。可以得出结论,所设计的口腔粘附控释片有可能克服目前市售盐酸乐卡地平制剂口服生物利用度差且不稳定的缺点。